Merck & Co. (MRK) : Newman Dignan Sheerar scooped up 1,020 additional shares in Merck & Co. during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Apr 11, 2016. The investment management firm now holds a total of 64,406 shares of Merck & Co. which is valued at $3,615,753.Merck & Co. makes up approximately 2.60% of Newman Dignan Sheerar’s portfolio.
Merck & Co. closed down -0.31 points or -0.55% at $56.14 with 84,34,440 shares getting traded on Friday. Post opening the session at $56.53, the shares hit an intraday low of $55.88 and an intraday high of $56.55 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
Other Hedge Funds, Including , Lenox Wealth Advisors reduced its stake in MRK by selling 23 shares or 0.6% in the most recent quarter. The Hedge Fund company now holds 3,790 shares of MRK which is valued at $212,771. Merck & Co. makes up approx 0.06% of Lenox Wealth Advisors’s portfolio.First Premier Bank boosted its stake in MRK in the latest quarter, The investment management firm added 665 additional shares and now holds a total of 16,587 shares of Merck & Co. which is valued at $913,114. Merck & Co. makes up approx 0.74% of First Premier Bank’s portfolio. Indiana Trust Investment Management Co sold out all of its stake in MRK during the most recent quarter. The investment firm sold 20,879 shares of MRK which is valued $1,149,389. Graybill Bartz Assoc Ltd added MRK to its portfolio by purchasing 60,355 company shares during the most recent quarter which is valued at $3,322,543. Merck & Co. makes up approx 3.04% of Graybill Bartz Assoc Ltd’s portfolio.Lvm Capital Management Ltdmi reduced its stake in MRK by selling 200 shares or 1.78% in the most recent quarter. The Hedge Fund company now holds 11,018 shares of MRK which is valued at $606,541. Merck & Co. makes up approx 0.19% of Lvm Capital Management Ltdmi’s portfolio.
On the company’s financial health, Merck & Co. reported $0.93 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Feb 3, 2016. Analyst had a consensus of $0.91. The company had revenue of $10215.00 million for the quarter, compared to analysts expectations of $10355.20 million. The company’s revenue was down -2.5 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $0.87 EPS.
Many Wall Street Analysts have commented on Merck & Co.. Societe Generale Initiated Merck & Co. on Apr 6, 2016 to “Buy”, Price Target of the shares are set at $80.Merck & Co. was Downgraded by BofA/Merrill to ” Neutral” on Jan 27, 2016.
Merck & Co. Inc. is a global health care company. The Company offers health solutions through its prescription medicines vaccines biologic therapies and animal health products which it markets directly and through its joint ventures. The Companys Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents generally sold by prescription for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers hospitals government agencies and managed health care providers. The Animal Health segment discovers develops manufactures and markets animal health products including vaccines. The Companys animal health products are sold to veterinarians distributors and animal producers.